NCT01386086

Aripiprazole and Resistant Postpartum Depression

Augmentation Therapy of Resistant Postpartum Depression With Aripiprazole

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

Currently there are no controlled data on the management of postpartum depression that fails to respond to adequate antidepressant therapy. The investigators recently reported that a large number of patients responded to the addition of atypical neuroleptics after having failed antidepressant trials. Aripiprazole used adjunctively to antidepressants is effective in patients with resistant depression but it has not been studied in patients with resistant postpartum depression. The investigators propose to conduct a 6 week open-label study to assess the effectiveness and tolerability of aripiprazole used adjunctively to antidepressants in patients with resistant postpartum depression.

Conditions

• Postpartum Depression

Interventions

Type	Name	Description
DRUG	aripiprazole	The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily

Timeline

• Start date: 2011-06-01
• Primary completion: 2013-11-01
• Completion: 2013-11-01
• First posted: 2011-06-30
• Last updated: 2016-03-17

Locations

1 site across 1 country: Canada